P/D Surgery for Mesothelioma Improves Quality of Life Regardless of Lung Function

P/D Surgery for Mesothelioma

Japanese researchers say P/D surgery for mesothelioma improves quality of life for most patients, even if their lung function gets worse.  Doctors at the Hyogo College of Medicine tracked the cases of forty-five patients who had P/D surgery for mesothelioma between 2014 and 2018.  Lung function tests showed most pleural mesothelioma patients could not breathe as well after surgery as they did before. Their energy, vitality, and social functioning also decreased. But patients reported better mental health after surgery and significantly less pain.  The researchers conclude that quality of life after P/D surgery for mesothelioma may have less to do with breathing than previously thought.  What is P/D Surgery for Mesothelioma? Pleural mesothelioma tumors grow on the pleura, a thin … Continue reading P/D Surgery for Mesothelioma Improves Quality of Life Regardless of Lung Function »

Mesothelioma Surgeries Carry Similar Mortality Risk, Study Finds

mesothelioma surgeries

The two major types of mesothelioma surgeries carry similar risk of death, according to a new study from cancer researchers in Japan.  One surgery involves removing the diseased pleural lining and one of the lungs. The other surgery removes many of the same tissues but leaves the lungs intact.  Surgeons around the world are divided as to which of these mesothelioma surgeries is best. Mesothelioma patients have more complications with lung-removing surgery. But some studies suggest it could lead to longer survival.  The 4-year Japanese study included more than 600 patients. It suggests that the likelihood of dying is similar with either of these mesothelioma surgeries.  Surgical Treatment of Pleural Mesothelioma Pleural mesothelioma is the most common type of asbestos … Continue reading Mesothelioma Surgeries Carry Similar Mortality Risk, Study Finds »

Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments

different mesothelioma subtypes

A group of European pathologists say the different mesothelioma subtypes have significant differences in their pattern of gene expression. Exploiting these differences could help scientists craft more effective mesothelioma treatments.  Asbestos exposure is the primary cause of mesothelioma. But doctors know that genetics play a role, too. Newly-approved immunotherapy drugs target proteins expressed by specific genes. But these drugs work much better in some mesothelioma patients than they do in others.  The new study suggests that differences in the genetic profiles of different mesothelioma subtypes could help explain why.  Immunotherapy Drugs for Mesothelioma Immunotherapy is an up-and-coming treatment approach for mesothelioma and other cancers. It harnesses the power of the person’s immune system to fight cancer.  In people with mesothelioma, … Continue reading Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments »

Treatment Advances Fail to Improve Mesothelioma Survival Trends

mesothelioma survival trends

A new report shows mesothelioma survival trends have remained steady for decades, despite new drugs, new surgery techniques, and the introduction of pleural catheters.  The report comes from cancer researchers at Ottawa Hospital Cancer Centre in Canada. Canada has one of the world’s highest rates of malignant pleural mesothelioma. This is likely related to the country’s long history of asbestos production. To compile the new report, researchers compared mesothelioma outcomes in three different decades between 1991 and 2019. There were surprisingly few differences in mesothelioma survival trends in the three decades.  Mesothelioma’s Destructive History Pleural mesothelioma is a virulent cancer of the pleural membrane. This is the tissue or mesothelium that surrounds the lungs. It is thin but flexible and … Continue reading Treatment Advances Fail to Improve Mesothelioma Survival Trends »

Mesothelioma-Related Weight Loss: Synthetic Cannabinoid Might Help

mesothelioma-related weight loss

The first patient has been treated in the trial of a new drug that might help people suffering from mesothelioma-related weight loss. The drug is a synthetic cannabinoid called ART27.13. A cannabinoid is a compound that acts on the CB1 and CB2 receptors of the endocannabinoid system. There are a number of cannabinoid drugs on the market. But several of them have significant side effects, including effects on the brain.  Preclinical data on ART27.13 suggest that it may stimulate the appetite and counter mesothelioma-related weight loss with fewer unwanted side effects. The Cancer Appetite Recovery Study (CAReS) is a Phase I trial to test it in people. The Danger of Mesothelioma-Related Weight Loss Over 60 percent of late-stage cancer patients … Continue reading Mesothelioma-Related Weight Loss: Synthetic Cannabinoid Might Help »

Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests

triple-modality therapy

A Canadian study suggests that triple-modality therapy with radiotherapy, immunotherapy, and surgery may extend the lives of people with malignant pleural mesothelioma.  Pleural mesothelioma is an intractable cancer with a poor prognosis. It mainly affects people who have lived or worked around asbestos.  There is no cure for mesothelioma. People who have the best mesothelioma outcomes usually have a combination of treatments.  Now, scientists at Toronto General Hospital’s Research Institute say a triple-modality therapy they tested in mice might have the power to extend human lives, too. Multi-modal Mesothelioma Treatment Pleural mesothelioma is a fast-growing cancer that starts on the membrane around the lungs. Many mesothelioma patients die less than a year after diagnosis.  There is no single accepted treatment … Continue reading Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests »

Long-Term Mesothelioma Survival With Immunotherapy Combination

immunotherapy combination

An immunotherapy combination of tremelimumab and durvalumab has resulted in long-term survival for some mesothelioma patients in a new follow-up Italian study.  Tremelimumab and durvalumab (Imfinzi) received orphan drug designation from the FDA last year for liver cancer. Now, it looks like this immunotherapy combination could help some people with the rare asbestos cancer, too.  Mesothelioma patients who had the best results in the new study were those with a high number of mutated genes. Mesothelioma is often fatal within a year. But the longest-living patient in the study survived for more than 41 months.  Immunotherapy Combination Blocks Key Proteins White blood cells have the power to help combat mesothelioma. But a protein called CTLA-4 can block that ability. Tremelimumab … Continue reading Long-Term Mesothelioma Survival With Immunotherapy Combination »

Canadian Study Highlights Occupational Mesothelioma Risk

occupational mesothelioma risk

A new study of more than 2 million Canadian workers is shining a spotlight on the occupational mesothelioma risk from asbestos exposure in several industries. The study included data on 2.18 million workers in the Occupational Disease Surveillance System (ODSS). These workers were employed from 1983 to 2014. The researchers followed the workers for years to see how many of them developed mesothelioma or a chronic lung disease called asbestosis.  They compiled the data on which industries had the most diagnoses. The results paint a sobering picture of the occupational mesothelioma risk to thousands of industrial workers. Asbestos and the Link to Mesothelioma Asbestos is a fibrous mineral that occurs naturally in the soil in many parts of the world. … Continue reading Canadian Study Highlights Occupational Mesothelioma Risk »

CRS/HIPEC Procedure Has Improved Over Time, Study Finds

CRS/HIPEC Procedure

A new French study contains some good news for people considering the CRS/HIPEC procedure for peritoneal mesothelioma.  The CRS/HIPEC procedure combines surgical resection with localized chemotherapy. Its aim is to remove or destroy as many mesothelioma cells as possible in the abdomen.  French researchers studied the evolution of the procedure over time. They discovered that it has improved. As a result, people with peritoneal cancers like malignant mesothelioma are living longer.  Cytoreductive Surgery for Mesothelioma Peritoneal mesothelioma causes tumors on the peritoneal membrane that lines the abdomen. Like other forms of mesothelioma, the cause is usually asbestos exposure.  Cytoreductive surgery (CRS) is an operation to remove tumors from the abdomen. Mesothelioma tumors may be confined to the peritoneal membrane, or … Continue reading CRS/HIPEC Procedure Has Improved Over Time, Study Finds »

Prognostic Value of PET/CT in Pleural Mesothelioma Patients

prognostic value of PET/CT

New data highlights the prognostic value of PET/CT scans for patients with malignant pleural mesothelioma. Pleural mesothelioma is a rare malignancy with a poor prognosis. But some patients tend to do better than others. Scientists are always looking for better ways to predict which patients will respond best to which treatment. A new Turkish study focused on the prognostic value of scans that measure tumor volume and metabolic activity. They conclude that PET/CT is a valuable way to predict mesothelioma outcomes. Doctors can use the information to help plan for chemotherapy or surgical treatment.  How PET/CT Scans Work Doctors have been aware of malignant mesothelioma since the 1930s. That is when it first started appearing among asbestos workers. But there … Continue reading Prognostic Value of PET/CT in Pleural Mesothelioma Patients »

Get your free copy of
“Surviving Mesothelioma” Today!